Hypervirulent BI/NAP1/027 strains of Clostridium difficile have been associated with increased mortality of C. difficile infection (CDI). The emergence of highly fluoroquinolone (FLQ)-resistant BI/NAP1/027 strains suggests that FLQ exposure may be a risk factor for CDI development. However, the mechanism for this is not clear. We compared the effects of subinhibitory concentrations of ciprofloxacin on Toxin A and B gene expression and protein production in recent (strain 039) and historical (strain 5325) BI/NAP1/027 clinical isolates with high- and low-level ciprofloxacin resistance, respectively. In the highly ciprofloxacin-resistant isolate (strain 039), ciprofloxacin significantly and dose-dependently increased Toxin A gene expression and shifted its expression to earlier in its growth cycle; TcdB gene expression also increased but was less sensitive to low-dose ciprofloxacin. Maximal Toxin A/B production (4 ng ml−1) was increased twofold and occurred significantly earlier than in the untreated control. In strain 5325, ciprofloxacin at 0.25×MIC markedly increased both tcdA and tcdB expression but their temporal dynamics were unchanged. Maximal toxin production (250 ng ml−1) was reduced approximately threefold compared with that of the untreated control. These results demonstrate significant differences in ciprofloxacin-induced toxin gene expression and protein production among BI/NAP1/027 isolates, and offer a new paradigm for FLQ-associated CDI caused by recent, highly antibiotic-resistant strains.
AdamsD. A., RiggsM. M., DonskeyC. J.2007; Effect of fluoroquinolone treatment on growth of and toxin production by epidemic and nonepidemic Clostridium difficile strains in the cecal contents of mice. Antimicrob Agents Chemother 51:2674–2678 [View Article][PubMed]
CarterG. P., DouceG. R., GovindR., HowarthP. M., MackinK. E., SpencerJ., BuckleyA. M., AntunesA., KotsanasD. et al.2011; The anti-sigma factor TcdC modulates hypervirulence in an epidemic BI/NAP1/027 clinical isolate of Clostridium difficile. PLoS Pathog 7:e1002317 [View Article][PubMed]
CLSI (2004).Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria; Approved Standard, 6th ed. NCCLS document M11-A6. Wayne, PA: NCCLS
DeshpandeA., PantC., JainA., FraserT. G., RolstonD. D.2008; Do fluoroquinolones predispose patients to Clostridium difficile associated disease? A review of the evidence. Curr Med Res Opin 24:329–333 [View Article][PubMed]
DhallaI. A., MamdaniM. M., SimorA. E., KoppA., RochonP. A., JuurlinkD. N.2006; Are broad-spectrum fluoroquinolones more likely to cause Clostridium difficile-associated disease?. Antimicrob Agents Chemother 50:3216–3219 [View Article][PubMed]
DrummondL. J., SmithD. G., PoxtonI. R.2003; Effects of sub-MIC concentrations of antibiotics on growth of and toxin production by Clostridium difficile. J Med Microbiol 52:1033–1038 [View Article][PubMed]
GerberM., WalchC., LofflerR., TischendorfK., ReischlU., AckermannG.2008; Effect of sub-MIC concentrations of metronidazole, vancomycin, clindamycin and linzolid on toxin gene transcription and production in Clostridium difficile. J Med Microbiol 57:776–783 [View Article]
HondaT., HernadezI., KatohT., MiwataniT.1983; Stimulation of enterotoxin production of Clostridium difficile by antibiotics. Lancet 321:655 [View Article][PubMed]
LivakK. J., SchmittgenT. D.2001; Analysis of relative gene expression data using real-time quantitative PCR and the 2–ΔΔT method. Methods 25:402–408 [View Article][PubMed]
McFarlandL. V., ClarridgeJ. E., BenedaH. W., RaugiG. J.2007; Fluoroquinolone use and risk factors for Clostridium difficile-associated disease within a Veterans Administration health care system. Clin Infect Dis 45:1141–1151 [View Article][PubMed]
NovellM. J., MorrealeC. A.2010; The relationship between inpatient fluoroquinolone use and Clostridium difficile-associated diarrhea. Ann Pharmacother 44:826–831 [View Article][PubMed]
OnderdonkA. B., LoweB. R., BartlettJ. G.1979; Effect of environmental stress on Clostridium difficile toxin levels during continuous cultivation. Appl Environ Microbiol 38:637–641[PubMed]
PultzN. J., DonskeyC. J.2005; Effect of antibiotic treatment on growth of and toxin production by Clostridium difficile in the cecal contents of mice. Antimicrob Agents Chemother 49:3529–3532 [View Article][PubMed]
RuizJ.2003; Mechanisms of resistance to quinolones: target alterations, decreased accumulation and DNA gyrase protection. J Antimicrob Chemother 51:1109–1117 [View Article][PubMed]
SaxtonK., BainesS. D., FreemanJ., O’ConnorR., WilcoxM. H.2009; Effects of exposure of Clostridium difficile PCR ribotypes 027 and 001 to fluoroquinolones in a human gut model. Antimicrob Agents Chemother 53:412–420 [View Article][PubMed]
TanK. S., WeeB. Y., SongK. P.2001; Evidence for holin function of tcdE gene in the pathogenicity of Clostridium difficile. J Med Microbiol 50:613–619[PubMed]